Nippon India Pharma Fund - IDCW - Direct Plan

Other Plans and Options
  • (-0.36%)Nav, as on 15-09-2025

  • Previous Nav

  • Net Change on 15-09-2025

  • PersonalFN Rating

  • Assets (Cr.)

  • Expense Ratio

Fund Overview IDCW | Direct Plan

  • Fund House

  • Launch Date

  • Benchmark

  • Minimum Investment (₹)

  • Minimum Addl Investment (₹)

  • Exit Load (%)

  • Minimum SIP Investment (₹)

  • Minimum STP Investment (₹)

  • Minimum SWP Investment (₹)

  • 52 Week Low Nav (₹)

  • 52 Week Low Nav Date

  • 52 Week High Nav (₹)

  • 52 Week High Nav Date

Fund Objective

The primary investment objective of the Scheme is to generate consistent returns by investing in equity / equity related or fixed income securities of Pharma and other associated companies

Fund Performance

Scheme Name 1-Month Return (%) 3-Month Return (%) 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Since Inception
NIPPON INDIA PHARMA FUND - DIRECT Plan - IDCW Option 2.11 1.06 -0.74 23.97 20.15 17.99
BSE Health Care - TRI N/A N/A N/A N/A N/A N/A
BSE SENSEX - TRI N/A N/A N/A N/A N/A N/A

Returns upto 1 year is Absolute, and above 1 year are Compounded Annualised

Peer Fund Comparison

Scheme Name Launch Date Ratings 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Expense Ratio (%) Assets (Cr.)
NIPPON INDIA PHARMA FUND - DIRECT Plan - IDCW Option Jan 01, 2013 -0.74 23.97 20.15 0.89 8,357.03
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund - Direct Plan - IDCW Option Jul 13, 2018 4.30 29.47 22.88 1.04 6,161.81
SBI Healthcare Opportunities Fund - Direct Plan - Income Distribution cum Capital Withdrawal Option (IDCW) Jan 01, 2013 4.69 27.49 22.11 0.91 3,963.38
Mirae Asset Healthcare Fund Direct IDCW Jul 02, 2018 1.43 23.64 20.90 0.49 2,795.84
TATA India Pharma & Health Care Fund Direct Plan - Payout of Income Distribution cum capital withdrawal option Dec 28, 2015 0.02 25.34 21.21 0.62 1,308.56
TATA India Pharma & Healthcare Fund Direct Plan - Reinvestment of Income Distribution cum capital withdrawal option Dec 28, 2015 0.02 25.34 21.21 0.62 1,308.56

Fund Holdings as on 31-August-2025

  • Sun Pharmaceutical Industries Limited

  • Divi's Laboratories Limited

  • Cipla Limited

  • Lupin Limited

  • Apollo Hospitals Enterprise Limited

  • Dr. Reddy's Laboratories Limited

  • MedPlus Health Services Limited

  • Vijaya Diagnostic Centre Limited

  • GlaxoSmithKline Pharmaceuticals Limited

  • Gland Pharma Limited

  • Ajanta Pharma Limited

  • Thyrocare Technologies Limited

  • Abbott India Limited

  • Sai Life Sciences Limited

  • Dr. Lal Path Labs Limited

  • Zydus Lifesciences Limited

  • Mankind Pharma Limited

  • Narayana Hrudayalaya Limited

  • Aurobindo Pharma Limited

  • JB Chemicals & Pharmaceuticals Limited

  • Alkem Laboratories Limited

  • Pfizer Limited

  • Biocon Limited

  • Sanofi India Limited

  • Suraksha Diagnostic Limited

  • Sanofi Consumer Healthcare India Limited

  • IPCA Laboratories Limited

  • Torrent Pharmaceuticals Limited

  • Fortis Healthcare Limited

  • Anthem Biosciences Limited

  • Syngene International Limited

  • Akums Drugs and Pharmaceuticals Limited

  • Emcure Pharmaceuticals Limited

  • AstraZeneca Pharma India Limited

  • Indoco Remedies Limited

  • Orchid Pharma Limited

  • Triparty Repo

  • Concord Biotech Limited

  • Net Current Assets

  • Cash Margin - CCIL

View More

  • Pharmaceuticals & Drugs

  • Hospital & Healthcare Services

  • Retailing

  • Business Support

  • Miscellaneous

View More

Fund Manager

Most Recent Dividend

  • 21/02/2025

  • 26/02/2024

  • 28/02/2022

  • 01/03/2021

  • 02/03/2020

  • 05/03/2019

  • 05/03/2018

  • 06/03/2017

  • 08/03/2016

  • 02/02/2015

  • 17/02/2014

  • Cash

  • Equity

View More

About Nippon India Pharma Fund

Scheme Analysis

Nippon India Pharma Fund is a Equity - Sectoral Fund - Pharma & Health Care fund and belongs to Nippon India Mutual Fund. It was launched on 01-Jan-2013 and currently has an AUM of ₹8,357.03 crore. Nippon India Pharma Fund is benchmarked against BSE Health Care - TRI as primary index and BSE SENSEX - TRI as secondary index.

The NAV of Nippon India Pharma Fund ended down ₹-0.61(-0.36%)yesterday to ₹170.2838.

Among its top 3 holdings the fund has exposure to Sun Pharmaceutical Industries Limited, and

The Nippon India Pharma Fund is managed by Sailesh Raj Bhan .

Fund House Contact

4th Floor, Tower A, Peninsula Business Park, Ganapatrao Kadam Marg, Lower Parel (W) Mumbai - 400 013

022-68087000
022-68087097